BOSTON -- (BUSINESS WIRE) -- EnBiotix, Inc., is delighted to announce that its scientific founder and Chairman of its Scientific Advisory Board, Professor James J. Collins, was elected to the National Academy of Sciences on April 29, 2014. Dr. Collins is the William F. Warren Distinguished Professor, University Professor and Professor of Biomedical Engineering; Director, Center of Synthetic Biology, Boston University and the Wyss Institute for Biologically Inspired Engineering, Harvard University; and Investigator of the Howard Hughes Medical Institute.
Dr. Collins has achieved a particularly rare status, joining a small and prestigious group of scientists that are members of all three national scientific academies. In addition to the National Academy of Sciences, he has been a member of the National Academy of Engineering since 2011 and the Institute of Medicine since 2012.
“All of us at EnBiotix heartily congratulate Professor Collins on joining this highly distinguished group of researchers. His appointment to the Academy is further recognition of the groundbreaking work that he is pursuing,” said Jeffrey D. Wager, M.D., CEO of EnBiotix. “We are deeply honored to be working with Dr. Collins on our mission to radically transform the field of antibiotics for the benefit of patients, their caregivers and healthcare delivery systems worldwide. In contrast to most other antibiotic companies which are focused on a single molecule, series or new class of agents, the platforms invented by Dr. Collins enable the development of novel potentiators with the potential to broadly reinvigorate the entire armamentarium of antibiotics.”
Prof. Collins’ work has focused on synthetic biology and systems biology with an emphasis on utilizing network biology to understand antibiotic action and bacterial defense mechanisms.
About EnBiotix, Inc.
EnBiotix, Inc., is an “engineered antibiotics” company focused on developing and commercializing the antibacterial and antifungal discoveries of the laboratory of Prof. James J. Collins. The company, co-founded by Boston University and Apeiron Partners LLC, has licensed a broad portfolio of technology platforms to support development of transformational antibiotic and antifungal therapies. www.enbiotix.com
EBX-001, EnBiotix’s lead program, is a potential front-line therapy for the treatment of lung infections in cystic fibrosis (CF) patients and has been developed from our systems biology and anti-persister platform. There are over 70,000 patients suffering with CF worldwide, with upwards of 85% having to be regularly treated with tobramycin beginning sometime between the ages of 18 and 35. EBX-001 is a potentiator of tobramycin, enhancing its bactericidal activity 10,000 times against Pseudomonas aeruginosa persisters, the most common infectious organism in CF patients, with a variety of in vitro, biofilm and animal model work strongly supportive of its utility. Broad IP protection has been filed around EBX-001 and its analogs, and there are significant opportunities for expansion into additional indications, such as non-CF bronchiectasis, as well.
About EnBiotix’s Engineered Bacteriophages
EnBiotix’s engineered bacteriophages can deliver a variety of antibacterial “payloads.” EnBiotix is pursuing three payload embodiments: a biofilm-degrading enzyme payload which has broad applicability in cystic fibrosis, other lung infections, prosthetic joint infections, and catheter related infections, among others; payloads that can exquisitely target a wide variety of bacterial resistance mechanisms (such as DNA-repair and efflux pump mechanisms); and anti-microbial peptides that can be expressed inside the targeted bacteria. These constructs have demonstrated dramatic potentiation of all three major antibiotic drug classes (beta-lactams, quinolones, aminoglycosides) and the ability to reverse resistance.